• Explore /
  • Poster
  • / Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.

Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.

Abstract Poster

Authors

null

Vincenzo Gennusa

AOUP "Paolo Giaccone", Palermo, Italy

Vincenzo Gennusa , Calogero Saieva , Richard M. Lee-Ying , Pier Vitale Nuzzo , Gian Paolo Spinelli , Elisa Zanardi , Giuseppe Fotia , Sabrina Rossetti , Loana Bueno Valenca , Anna Patrikidou , Livia Andrade , Ricardo Pereira Mestre , Giuseppe Fornarini , Giuseppe Procopio , Daniele Santini , Christopher Sweeney , Daniel Yick Chin Heng , Ugo De Giorgi , Antonio Russo , Edoardo Francini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 166)

DOI

10.1200/JCO.2023.41.6_suppl.166

Abstract #

166

Poster Bd #

F4

Abstract Disclosures

Similar Posters

First Author: Cora N. Sternberg

First Author: Mehmet Asim Bilen

First Author: Mehmet Asim Bilen

First Author: Simon J. Crabb